Codagenix, Inc.
πΊπΈUnited States
- Country
- πΊπΈUnited States
- Ownership
- Holding
- Established
- 2011-08-01
- Employees
- 1
- Market Cap
- -
- Website
- http://www.codagenix.com
Clinical Trials
8
Active:1
Completed:6
Trial Phases
1 Phases
Phase 1:8
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (8 trials with phase data)β’ Click on a phase to view related trials
Phase 1
8 (100.0%)A Study of CodaLytic, an Intratumoral Oncolytic Virus, in Patients With Breast Cancer
Phase 1
Withdrawn
- Conditions
- Neoplasm MetastasisBreast Neoplasms
- First Posted Date
- 2022-10-31
- Last Posted Date
- 2023-10-18
- Lead Sponsor
- Codagenix, Inc
- Registration Number
- NCT05600582
- Locations
- πΊπΈ
Dana Farber Cancer Institute, Boston, Massachusetts, United States
πΊπΈGabrail Cancer Center, Canton, Ohio, United States
Safety and Immunogenicity of COVI-VAC as a Booster Dose in Adults Previously Vaccinated Against COVID-19
Phase 1
Completed
- Conditions
- COVID-19SARS-CoV-2
- First Posted Date
- 2022-02-10
- Last Posted Date
- 2023-01-13
- Lead Sponsor
- Codagenix, Inc
- Target Recruit Count
- 20
- Registration Number
- NCT05233826
- Locations
- π¬π§
HMR, London, United Kingdom
Intramuscular CodaVax-H1N1 in Healthy Adults
Phase 1
Completed
- Conditions
- Influenza, Human
- Interventions
- First Posted Date
- 2022-02-03
- Last Posted Date
- 2024-05-31
- Lead Sponsor
- Codagenix, Inc
- Target Recruit Count
- 69
- Registration Number
- NCT05223179
- Locations
- π¦πΊ
Lis Gilmour, Senior Project Manager, Morayfield, Queensland, Australia
Safety and Immunogenicity of CodaVax-RSV in Seropositive and Seronegative Children
Phase 1
Active, not recruiting
- Conditions
- Respiratory Syncytial Virus Infections
- Interventions
- Biological: Normal Saline
- First Posted Date
- 2021-06-09
- Last Posted Date
- 2025-02-06
- Lead Sponsor
- Codagenix, Inc
- Target Recruit Count
- 51
- Registration Number
- NCT04919109
- Locations
- πΊπΈ
Velocity, West Jordan, Utah, United States
πΏπ¦University of Witwatersrand (WITS)/Vaccines and Infectious Diseases Analytics (VIDA), Johannesburg, South Africa
Safety and Immunogenicity of COVI-VAC, a Live Attenuated Vaccine Against COVID-19
Phase 1
Completed
- Conditions
- COVID-19
- First Posted Date
- 2020-11-06
- Last Posted Date
- 2022-06-28
- Lead Sponsor
- Codagenix, Inc
- Target Recruit Count
- 48
- Registration Number
- NCT04619628
- Locations
- π¬π§
hVIVO, London, United Kingdom
- Prev
- 1
- 2
- Next
News
No news found